288 related articles for article (PubMed ID: 15326376)
1. Chk1, but not Chk2, is involved in the cellular response to DNA damaging agents: differential activity in cells expressing or not p53.
Carrassa L; Broggini M; Erba E; Damia G
Cell Cycle; 2004 Sep; 3(9):1177-81. PubMed ID: 15326376
[TBL] [Abstract][Full Text] [Related]
2. Chk1 is dispensable for G2 arrest in response to sustained DNA damage when the ATM/p53/p21 pathway is functional.
Lossaint G; Besnard E; Fisher D; Piette J; Dulić V
Oncogene; 2011 Oct; 30(41):4261-74. PubMed ID: 21532626
[TBL] [Abstract][Full Text] [Related]
3. Elevated cyclin G2 expression intersects with DNA damage checkpoint signaling and is required for a potent G2/M checkpoint arrest response to doxorubicin.
Zimmermann M; Arachchige-Don AS; Donaldson MS; Dallapiazza RF; Cowan CE; Horne MC
J Biol Chem; 2012 Jun; 287(27):22838-53. PubMed ID: 22589537
[TBL] [Abstract][Full Text] [Related]
4. Drug discovery targeting Chk1 and Chk2 kinases.
Zhou BB; Sausville EA
Prog Cell Cycle Res; 2003; 5():413-21. PubMed ID: 14593735
[TBL] [Abstract][Full Text] [Related]
5. Knockdown of Chk1 sensitizes human colon carcinoma HCT116 cells in a p53-dependent manner to lidamycin through abrogation of a G2/M checkpoint and induction of apoptosis.
Pan Y; Ren KH; He HW; Shao RG
Cancer Biol Ther; 2009 Aug; 8(16):1559-66. PubMed ID: 19502782
[TBL] [Abstract][Full Text] [Related]
6. Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implications for cancer therapy.
Xiao Z; Xue J; Sowin TJ; Zhang H
Mol Cancer Ther; 2006 Aug; 5(8):1935-43. PubMed ID: 16928813
[TBL] [Abstract][Full Text] [Related]
7. ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis.
Pabla N; Huang S; Mi QS; Daniel R; Dong Z
J Biol Chem; 2008 Mar; 283(10):6572-83. PubMed ID: 18162465
[TBL] [Abstract][Full Text] [Related]
8. Differential roles for checkpoint kinases in DNA damage-dependent degradation of the Cdc25A protein phosphatase.
Jin J; Ang XL; Ye X; Livingstone M; Harper JW
J Biol Chem; 2008 Jul; 283(28):19322-8. PubMed ID: 18480045
[TBL] [Abstract][Full Text] [Related]
9. Dual regulation of Cdc25A by Chk1 and p53-ATF3 in DNA replication checkpoint control.
Demidova AR; Aau MY; Zhuang L; Yu Q
J Biol Chem; 2009 Feb; 284(7):4132-9. PubMed ID: 19060337
[TBL] [Abstract][Full Text] [Related]
10. UCN-01 inhibits p53 up-regulation and abrogates gamma-radiation-induced G(2)-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1.
Yu Q; La Rose J; Zhang H; Takemura H; Kohn KW; Pommier Y
Cancer Res; 2002 Oct; 62(20):5743-8. PubMed ID: 12384533
[TBL] [Abstract][Full Text] [Related]
11. Bendamustine induces G2 cell cycle arrest and apoptosis in myeloma cells: the role of ATM-Chk2-Cdc25A and ATM-p53-p21-pathways.
Gaul L; Mandl-Weber S; Baumann P; Emmerich B; Schmidmaier R
J Cancer Res Clin Oncol; 2008 Feb; 134(2):245-53. PubMed ID: 17653574
[TBL] [Abstract][Full Text] [Related]
12. The impact of S- and G2-checkpoint response on the fidelity of G1-arrest by cisplatin and its comparison to a non-cross-resistant platinum(IV) analog.
He G; Kuang J; Khokhar AR; Siddik ZH
Gynecol Oncol; 2011 Aug; 122(2):402-9. PubMed ID: 21592546
[TBL] [Abstract][Full Text] [Related]
13. Stalled replication induces p53 accumulation through distinct mechanisms from DNA damage checkpoint pathways.
Ho CC; Siu WY; Lau A; Chan WM; Arooz T; Poon RY
Cancer Res; 2006 Feb; 66(4):2233-41. PubMed ID: 16489026
[TBL] [Abstract][Full Text] [Related]
14. Increasing cisplatin sensitivity by schedule-dependent inhibition of AKT and Chk1.
Duan L; Perez RE; Hansen M; Gitelis S; Maki CG
Cancer Biol Ther; 2014; 15(12):1600-12. PubMed ID: 25482935
[TBL] [Abstract][Full Text] [Related]
15. Defective p53 signaling in p53 wild-type tumors attenuates p21waf1 induction and cyclin B repression rendering them sensitive to Chk1 inhibitors that abrogate DNA damage-induced S and G2 arrest.
Levesque AA; Fanous AA; Poh A; Eastman A
Mol Cancer Ther; 2008 Feb; 7(2):252-62. PubMed ID: 18281511
[TBL] [Abstract][Full Text] [Related]
16. Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2.
Carlessi L; Buscemi G; Larson G; Hong Z; Wu JZ; Delia D
Mol Cancer Ther; 2007 Mar; 6(3):935-44. PubMed ID: 17363488
[TBL] [Abstract][Full Text] [Related]
17. p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage.
Reinhardt HC; Aslanian AS; Lees JA; Yaffe MB
Cancer Cell; 2007 Feb; 11(2):175-89. PubMed ID: 17292828
[TBL] [Abstract][Full Text] [Related]
18. Tachpyridine, a metal chelator, induces G2 cell-cycle arrest, activates checkpoint kinases, and sensitizes cells to ionizing radiation.
Turner J; Koumenis C; Kute TE; Planalp RP; Brechbiel MW; Beardsley D; Cody B; Brown KD; Torti FM; Torti SV
Blood; 2005 Nov; 106(9):3191-9. PubMed ID: 16014567
[TBL] [Abstract][Full Text] [Related]
19. Cell cycle checkpoint proteins and cellular response to treatment by anticancer agents.
Damia G; Broggini M
Cell Cycle; 2004 Jan; 3(1):46-50. PubMed ID: 14657665
[TBL] [Abstract][Full Text] [Related]
20. Naphthalimides induce G(2) arrest through the ATM-activated Chk2-executed pathway in HCT116 cells.
Zhu H; Miao ZH; Huang M; Feng JM; Zhang ZX; Lu JJ; Cai YJ; Tong LJ; Xu YF; Qian XH; Ding J
Neoplasia; 2009 Nov; 11(11):1226-34. PubMed ID: 19881958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
